The Synthesis of Some Novel Polycyclic Chromans

Inger Reidun Aukrust, Einar Bakstad and Lars Skattebøl

Department of Chemistry, University of Oslo, P.O. Box 1033 Blindern, 0315 Oslo, Norway


Some polycyclic compounds containing the chroman skeleton have been prepared by a two-step reaction sequence, starting from 5,7-dihydroxy-4-chromanone derivatives. Reactions of the chromanones with methallylzinc bromide followed by acid treatment proceeded with ring formation to polycyclic chromenes. With one exception these were not isolated, but hydrogenated catalytically to the corresponding chromans, which were formed in 71–87% overall yields. Some further derivatization has been carried out. The compounds have been tested in vitro for antimalarial activity.

Dedicated to Professor Salo Gronowitz on the occasion of his 65th birthday.

In connection with the synthesis of robustadial A and B (1),1 two diastereomeric chroman derivatives isolated from the leaves of Eucalyptus robusta,2 we encountered the transformation in high yield of the chromanone 2a to the tricyclic chromene derivative 3a, which was subsequently transformed into the corresponding chroman 4a by catalytic hydrogenation. Although each of the reactions involved have some analogy in the literature,3 the combination seemed novel, and we have encountered only a few examples of this particular heterocyclic ring assembly in the literature.4,5 Furthermore, we were interested in analogues of robustadial for evaluation of antimalarial activity. The present paper describes the preparation of several compounds related to 4a, including derivatives with a ring system spiro-bonded at the 2-position of one of the chroman rings, and thus closely resembling the structure of robustadial.

Results and discussion

The dihydroxychromanones 2 were prepared by a Friedel-Crafts type condensation of phloroglucinol with the respective α,β-ununsaturated acid using aluminium trichloride in phosphoryl chloride, as previously reported.1 The chromanones were converted into the corresponding homoallylic alcohols with methallylzinc bromide in THF. The organozinc derivative was formed in a few minutes from the metal and methallyl bromide under ultrasound conditions.6 Because of the two hydroxy groups present in the chromanones the use of three equivalents of the organometallic compound was required, and the best results were actually obtained using an excess of this amount. The initially formed homoallylic alcohols were not isolated, but treated with aqueous 5% hydrochloric acid for a few minutes, to give the tricyclic chromenes 3. We subsequently discovered that additional acid was not required; cyclisation took place when a THF solution of the alcohol was heated for some time. The crude chromenes were subsequently hydrogenated catalytically in ethanol solution to the chromans 4, which were obtained in overall yields varying from 71 to 87%, based on the respective chromalone. The first two reactions were conveniently conducted as one-pot procedures. The structures were assigned on the basis of the spectroscopic data. The chromene 3a was isolated and purified in order to determine its structure; otherwise the intermediate chromenes were not isolated and characterized. In the case of 4a the presence of one hydroxy group was
ascertained by preparing the methylated derivative 5a, using methyl iodide and sodium carbonate in acetone. The chroman 4d was obtained as a 55:45 mixture of diastereomers, and in the case of 4e a 9:1 mixture was obtained, as shown by the NMR spectra. We were unable to separate these mixtures. A rationalization of the results is given in Scheme 1, using the conversion of the chromanone 2a as an example. The phenolic hydroxy group at the 5-position of the initially formed chromanol 6 undergoes acid-catalyzed addition to the double bond of the isobutenyl group, forming a new six-membered ring. The tricyclic alcohol 7 thus formed eliminates water to yield the chromene derivative 3a. Apparently the phenolic hydrogens are sufficiently acidic to exert a catalytic effect on both these reactions. Subsequent hydrogenation of the chromene afforded the corresponding chroman 4a. From unsymmetrically substituted analogs of 7, mixtures of regioisomeric chromenes were obtained as indicated by the spectral data. In chromenes containing a chiral carbon the double bond is diastereotopic, and hydrogenation may give rise to mixtures of stereoisomeric chromans. This was observed in the cases of 4d and 4e, which were formed as inseparable mixtures of diastereomers.

Since we were engaged in the synthesis of robustadial analogs for biological evaluation as potential antimalarial compounds, the incorporation of aldehyde functions into the chroman derivatives was of particular interest. The chroman 4a was used as a model substance in order to find a convenient formulation method. To our surprise, the introduction of two aldehyde groups was not an easy task. The monoaldehyde 5b was readily available by all the methods employed, but the dialdehyde 5c was formed only from the reaction of 4a with dichloromethyl methyl ether and titanium tetrachloride in dichloromethane. Subsequently, the dialdehyde 8 was also prepared by this procedure, but in both cases the yields were less than 50%. The hydroxy group of both aldehyde derivatives was methylated with methyl iodide in the usual way. Reaction of 4a with bromine at room temperature afforded the monobromide 9 as a crystalline compound in practically quantitative yield.

Compounds 4-6, 8 and 9 were tested in vitro for antimalarial activity against a resistant strain of Plasmodium falciparum. Several of the compounds exhibited activity, but not at a concentration that would be regarded as interesting.

Experimental

General. GLC analyses were performed on a 30 m capillary column of SP2100. IR spectra were recorded on a Perkin Elmer 1310 instrument. NMR spectra were obtained on Varian XL-300 and 200 and mass spectra on Micromass 7070 F instruments. Capillary melting points were taken on a Büchi SMP-20 apparatus and are uncorrected.

2,2,5,5-Tetramethyl-3,3a,4,4,4-tetrahydro-2H-pyrano[4,3,2-de]-1-benzopyran-8-ol (4a). A solution of methallyl bromide (31.5 g, 0.23 mol) in THF (100 ml) was added over 20 min to a suspension of activated zinc (47.5 g, 0.88 mol) in THF (200 ml) using ultrasound for stirring. After 1 h at room temperature the chromanone 2a (10.4 g, 50 mmol) in THF (150 ml) was added dropwise over 30 min. After 1 h at room temperature, aq. HCl (5%, 100 ml) was added and the mixture was stirred for 20 min. The organic phase was separated and the aq. phase extracted with ether. The combined organic phase was dried (MgSO₄) and the solvents evaporated off. The crude chromene 3a, m.p. 109–110°C (from CH₂Cl₂), was dissolved in ethanol (300 ml) and hydrogenated in a Parr apparatus using Pd/C (10%, 1.0 g) as the catalyst. Evaporation of solvents and purification by flash chromatography on silica gel (pet. ether–EtOAc 85:15) afforded the chroman 4a (10.9 g, 87%) as colorless crystals, m.p. 147–149°C, from EtOAc. 3a: IR (CHCl₃): 3560, 3400–3200, 1620, 1590, 1450, 1140 cm⁻¹. H NMR (300 MHz, CDCl₃): δ 1.31 (s, 6 H), 1.41 (s, 6 H), 2.31 (d, J 1.6 Hz, 2 H), 5.09 (t, 1 H), 5.89 (d, 1 H), 5.94 (d, 1 H). ¹³C NMR (75 MHz, CDCl₃): δ 27.68, 29.34 (CH₃), 39.50 (CH₂), 77.30, 78.08 (C), 96.54, 96.61 (CH), 101.32 (C), 120.50 (CH =), 124.08 (C =), 152.91, 153.84, 157.91 (C). 4a: IR (KBr): 3600, 3450–3200, 1650, 1600, 1455, 1140 cm⁻¹. H NMR (300 MHz, CDCl₃): δ 1.3–1.4 (m, 14 H),
5′,5′-Dimethyl-3′,3a′,4′,5′-tetrahydrospiro[cyclopentane-1,2′-2H|pyrano|4,3,2-de|1′]benzopyran-8′-ol (4a). The chromane 2b′ (2.5 g, 10.7 mmol) in THF (75 ml) was treated with methallyl bromide (7.5 g, 54.8 mmol) and activated zinc (13.4 g, 0.2 mol) in THF (170 ml) and the crude product was subsequently treated with acid, hydrogenated and purified as described for 4a. The chroman 4b (2.30 g, 78%) was obtained as colorless crystals, m.p. 153–154°C, from CH₂Cl₂, IR (CHCl₃): 3600, 3500–3200, 1600, 1440, 1140 cm⁻¹. ¹³C NMR (200 MHz, CDCl₃): δ 13.7 (s, 3 H), 1.42 (s, 3 H), 1.60–2.05 (m, 12 H), 2.85 (m, 1 H), 5.89 (s, 2 H). ¹H NMR (50 MHz, CDCl₃): δ 25.20, 25.40 (CH₂), 27.80 (CH), 31.90 (CH), 38.50, 38.70, 40.08, 41.20 (CH₃), 76.40, 87.90 (C), 95.70, 95.80 (CH), 101.20, 154.50, 156.00 (C–O). ⁵,⁵′-Dimethyl-3′,3a′,4′,5′-tetrahydrospiro[spirocyclohexane-1,2′-2H|pyrano|4,3,2-de|1′]benzopyran-8′-ol (4c). The chromane 2c′ (2.0 g, 8.0 mmol) in THF (50 ml) was treated with methallyl bromide (5.2 g, 38.0 mmol) and activated zinc (10.0 g, 0.15 mol) in THF (120 ml) and the crude product was subsequently treated with acid, hydrogenated and purified as described for 4a. The chroman 4c (1.85 g, 80%) was obtained as colorless crystals, m.p. 92–93°C (from CH₂Cl₂). IR (CHCl₃): 3580, 3500–3200, 1590, 1440, 1120 cm⁻¹. ¹H NMR (200 MHz, CDCl₃): δ 1.30 (m, 2 H), 1.39 (s, 3 H), 1.48 (s, 3 H), 1.50–1.70 (m, 7 H), 1.71–2.00 (m, 5 H), 2.88 (m, 1 H), 5.91 (dd, 2 H). ¹³C NMR (50 MHz, CDCl₃): δ 22.56 (CH₂), 22.80, 22.78, 26.83 (CH₂), 26.96 (CH₃), 31.28 (CH), 35.24, 38.99, 40.06, 40.27 (CH₃), 76.22, 76.80 (C), 95.44, 95.69 (CH), 101.50, 154.20, 155.90 (C–O). 3,3′,5′-Tetramethyl-3′,3a′,4′,5′-tetrahydrospiro[bicyclo[2.2.1]heptane-2,2′-2H|pyrano|4,3,2-de|1′]benzopyran-8′-ol (4d). The chromane 2d′ (9.0 g, 31.6 mmol) was treated with an excess of methallyl bromide (21.4 g, 0.15 mol) and zinc (37.9 g, 0.55 mol) in THF (230 ml), and the crude product was subsequently treated with acid, hydrogenated and purified as described for 4a. The chroman 4d (8.63 g, 82%) consisted of a 55:45 mixture of diastereomers which could not be separated, and the spectral data were recorded on the mixture. IR (CHCl₃): 3580, 3400–3300 (w), 1620, 1450, 1240, 1140 cm⁻¹. MS [Cl, (% rel. int.)]: m/z 329 (100), 328 (21). ¹H NMR (300 MHz, CDCl₃): δ 0.94–1.42 (m, 36 H), 1.53–1.82 (m, 6 H), 1.95–2.08 (m, 2 H), 2.12–2.40 (m, 4 H), 2.69 (m, 2 H), 4.44 (br s, 2 H), 5.85 (s, 4 H). ¹³C NMR (75 MHz, CDCl₃): Major isomer: δ 19.05 (CH₃), 22.49 (CH₂), 26.65, 24.95, 25.85 (CH₂), 29.32 (CH₃), 30.26 (CH₂), 34.18, 39.46 (CH₂), 45.71 (C), 49.05 (CH), 50.45 (CH), 75.37, 86.67 (C), 94.10 (CH), 100.30, 154.12, 154.62, 155.93 (C–O). Minor isomer: δ 22.03 (CH₃), 23.48 (CH₂), 22.80 (CH₃), 24.03 (CH₂), 25.43, 26.35, 30.12 (CH₃), 31.81, 34.48, 39.64 (CH₂), 44.62 (CH), 45.44 (C), 51.87 (CH), 75.10, 87.29 (C), 94.31 (CH), 100.39, 153.63, 155.22, 155.93 (C–O). 7,9-Diformyl-2,2,5,5-tetramethyl-3,3a′,4′,5′-tetrahydrospiro[bicyclo[2.2.1]heptane-2,2′-2H|pyrano|4,3,2-de|1′]benzopyran-8′-ol (5e). A solution of the chroman 4a (1.0 g, 4.0 mmol) in CH₂Cl₂ (50 ml) and TiCl₄ (3.03 g, 16 mmol) was cooled in ice, and dichloromethyl methyl ether (1.5 g, 13.0 mmol) was added with
stirring. Stirring was continued for 7 h after which aq. H₂SO₄ (5%, 20 ml) was added, and the organic phase was separated. The aq. phase was extracted with ether, and the combined organic phases were dried (MgSO₄). Evaporation of solvents followed by flash chromatography of the crude product gave the yellow dialdehyde 5c (580 mg, 48%). IR (CCl₄): 2960, 2930, 1735, 1675, 1200, 1125 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 1.44 (s, 6 H), 1.46 (dd, 2 H), 1.53 (s, 6 H), 1.95 (dd, J 13.2 Hz, 2 H), 2.85 (m, 1 H), 10.21 (s, 2 H). ¹³C NMR (75 MHz, CDCl₃): δ 21.77 (CH), 26.12, 29.83 (CH₃), 38.38 (CH₃), 78.77, 97.68 (C), 104.88, 162.55, 166.68 (C=O), 189.19, 189.29 (C=O). Methylation in the usual way afforded 5d (75%) as light yellow crystals, m.p. 138–140°C. IR (CDCl₃): 2980, 1820, 1790, 1670, 1450, 1130 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 1.45 (s, 6 H), 1.47 (dd, 2 H), 1.53 (s, 6 H), 1.97 (dd, 2 H), 2.90 (m, 1 H), 3.96 (dd, 3 H), 10.29 (s, 2 H). ¹³C NMR (75 MHz, CDCl₃): δ 22.11 (CH), 26.13, 29.78 (CH₃), 38.09 (CH₃), 63.89 (O–CH₃), 78.22, 102.95, 111.08, 161.13, 165.33 (C), 187.16 (C=O).

7,9-Diformyl-3,3',5',5'-tetramethyl-3,4',5'-tetrahydrospiro[bicyclo[2.2.1]heptane-2,2'-[2]H]pyran-4,3,3'-de]-1]benzopyran-8-ol (8a). A solution of the chroman 4a (1.25 g, 5.0 mmol) and bromine (1.02 g, 7.5 mmol) in CH₂Cl₂ (50 ml) cooled in ice, was treated with dichloromethyl methyl ether (1.10 g, 9.6 mmol) as described for 5c. Flash chromatography (silica gel, pet.ether–EtOAc 8:2) gave the dialdehyde 8a (0.52 g, 45%) as a yellow liquid, consisting of a 55:45 mixture of stereoisomers. These could not be separated and the spectral data were recorded on the mixture. IR (CCl₄): 2957, 2930, 1730, 1680, 1200, 1130 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 0.98 (m, 6 H), 0.99 (m, 6 H), 1.11–1.43 (m, 18 H), 1.52 (s, 6 H), 1.61 (m, 4 H), 1.86 (m, 4 H), 2.16 (m, 4 H), 2.34 (m, 2 H), 2.70 (m, 2 H), 10.13 (s, 1 H), 10.15 (s, 1 H), 10.20 (s, 1 H), 10.26 (s, 1 H). ¹³C NMR (75 MHz, CDCl₃): δ 21.65 (CH), 21.74, 21.94 (CH₃), 22.60, 22.80 (CH), 23.53, 23.92 (CH₂), 25.14, 25.74, 26.08, 26.31 (CH₃), 28.62 (CH₂), 29.64, 29.80 (CH₃), 31.05, 34.31, 34.58, 38.55, 38.69 (CH₃), 45.27, 45.45 (C), 46.28, 48.82, 50.22, 51.74 (CH), 77.95, 78.30, 90.82, 91.56, 98.23, 98.26, 104.31, 104.53, 105.27 (C), 163.00, 166.66, 166.92, 189.40, 189.80 (CH). Methylation in the usual way afforded 8b (73%) as a mixture of stereoisomers. The spectral data were recorded on the mixture. IR (film): 2960, 1685, 1625, 1570, 1445, 1300, 1145 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 0.88–1.58 (m, 36 H), 1.60–2.00 (m, 8 H), 2.10–2.60 (m, 4 H), 2.74 (m, 2 H), 3.90 (s, 3 H), 3.92 (s, 3 H), 10.22 (s, 1 H), 10.28 (s, 1 H), 10.30 (s, 1 H), 10.33 (s, 1 H).

Isomer I: ¹³C NMR (75 MHz, CDCl₃): δ 21.73 (CH₂), 22.13 (CH₂), 22.45 (CH₃), 23.99 (CH₂), 25.76, 26.18, 29.63 (CH₃), 30.87, 34.57, 38.50 (CH₃), 45.32 (C), 50.25, 51.76 (CH), 63.97 (CH₂O), 77.93, 90.95, 103.46, 110.41, 110.61, 160.69, 161.14, 165.79 (C), 186.95 (CH). Isomer II: ¹³C NMR (75 MHz, CDCl₃): δ 21.79 (CH₂), 22.45 (CH₂), 22.60 (CH₃), 23.62 (CH₂), 25.22, 26.18 (CH₃), 28.30 (CH₂), 29.80 (CH₃), 34.60, 38.41 (CH₃), 45.08 (C), 46.19, 48.88 (CH), 63.85 (CH₂O), 78.30, 90.21, 103.46, 110.84, 111.46, 160.86, 161.19, 165.50 (C), 186.70 (CH).

7-Bromo-2,2,5,5-tetramethyl-3,4,4,5-tetrahydro-2H-py- rano[4,3,2-de]-1-benzopyran-8-ol (9). A solution of the chroman 4a (1.25 g, 5.0 mmol) and bromine (1.02 g, 7.5 mmol) in CH₂Cl₂ (50 ml) was stirred at room temperature for 24 h. The crystalline residue remaining after evaporation of solvent was recrystallized from cyclohexane to give the bromide 9 (1.53 g, 93%), m.p. 172–173°C. ¹H NMR (300 MHz, CDCl₃): δ 1.37–1.55 (m, 14 H), 1.88 (dd, J 13.2 Hz, 2 H), 2.80 (m, 1 H), 5.80 (s, 1 H), 12.09 (s, 1 H). ¹³C NMR (75 MHz, CDCl₃): δ 22.08, 26.16 (CH), 30.01, 32.22 (CH₃), 38.47, 39.00 (CH₂), 77.11 (C), 95.15 (CH), 98.16, 110.88, 154.10, 157.28, 158.91 (C).

Acknowledgments. We wish to thank the Norwegian Council for Scientific Research for a stipend to one of us (I. R. A.).

References
9. Dr. David Warhurst, Department of Parasitology, London School of Hygiene and Tropical Medicine, University of London. Personal communication.

Received May 11, 1992.